This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Tasly Biopharmaceuticals Co., Ltd.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Ruijing Huang: Innovator in Non-Alcoholic Steatohepatitis Treatment
Introduction
Ruijing Huang is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of non-alcoholic steatohepatitis (NASH). His innovative approach has garnered attention in the medical community.
Latest Patents
Ruijing Huang holds a patent for a method of treating NASH using a long-acting mutant human fibroblast growth factor. The invention involves administering a long-acting mutant human fibroblast growth factor, specifically mPEG-CH—NH-mFGF21, to subjects in need. This new use represents a promising advancement in the treatment of non-alcoholic steatohepatitis.
Career Highlights
Huang is associated with Tasly Biopharmaceuticals Co., Ltd., where he continues to develop groundbreaking treatments. His work has positioned him as a key figure in the biopharmaceutical industry, focusing on innovative solutions for complex health issues.
Collaborations
He collaborates with notable colleagues, including Jian Li and Jun Han, to further enhance the research and development of effective treatments in the biopharmaceutical sector.
Conclusion
Ruijing Huang's contributions to the treatment of non-alcoholic steatohepatitis highlight his role as an influential inventor in the biopharmaceutical field. His innovative methods and collaborations continue to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile